CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 66 enrolled / 66 target
Drug / intervention
Control-IQ technology 2.0device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05014789
NCT05014789N/ACompletedOn Track (1.1/mo)Completion was 54mo ago
CompareCT.gov

A Control-IQ Technology 2.0 Feasibility Study in Adult and Adolescent Subjects

Tandem Diabetes Care, Inc.·interventional·Posted Aug 20, 2021·Updated Jun 24, 2026

In Brief

A clinical study evaluating Control-IQ technology 2.0 for Diabetes Mellitus, Type 1. Completed, enrolled 66 participants across 1 site.

Detailed Summary

The purpose of this study is to obtain preliminary safety and performance data on planned improvements to Control-IQ technology.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 1
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedAug 20, 2021
Enrollment StartAug 19, 2021
Primary CompletionDec 20, 2021
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 4.9 years ago

Arms & Interventions

Control-IQ 2.0 technology 2.0 on the t:slim X2 insulin pumpexperimental

After a run-in week, each subject will use different combinations of new features of the system each week, in random order, for 4 weeks, using the t:slim X2 insulin pump with Control-IQ technology 2.0. The first 5 subjects participated in a 48-hour supervised hotel phase before continuing in the outpatient setting.

Device: Control-IQ technology 2.0

Interventions

Control-IQ technology 2.0device

All subjects wearing the t:slim X2 insulin pump with Control-IQ technology 2.0, and wearing the Dexcom G6 sensor